Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis

Area of Science:

• Critical Care Medicine
• Immunology
• Pharmacology

Background:

• Septic shock is a leading cause of mortality globally, posing a significant healthcare challenge.
• The focus has shifted from pro-inflammatory responses to anti-inflammatory effects (sepsis-induced immunoparalysis) in sepsis pathophysiology.
• Sepsis-induced immunoparalysis increases vulnerability to secondary infections and is linked to poorer patient outcomes.

Purpose of the Study:

• To reevaluate current septic shock management strategies in light of the immunoparalysis hypothesis.
• To investigate the potential detrimental role of norepinephrine, a primary treatment for septic shock, in exacerbating sepsis-induced immunoparalysis.
• To explore the immunomodulatory effects of norepinephrine and alternative vasopressors.

Main Methods:

• Review of current understanding of sepsis immunologic pathophysiology.
• Detailed description of the immunomodulatory effects of norepinephrine and alternative vasopressors.
• Analysis of in vitro and animal data regarding norepinephrine's effects on immune response and bacterial growth.

Main Results:

• Norepinephrine may aggravate the development, extent, and duration of sepsis-induced immunoparalysis.
• In vitro and animal studies suggest norepinephrine has immunosuppressive and bacterial growth-promoting effects, potentially increasing infection susceptibility.
• Human evidence on norepinephrine's immunologic effects is circumstantial and lacks rigorous investigation.

Conclusions:

• Novel therapies for reversing immunoparalysis are under development.
• Norepinephrine's use may be detrimental in the context of sepsis-induced immunoparalysis.
• Alternatives like vasopressin, selepressin, angiotensin II, and phenylephrine may offer immunologic advantages, but human in vivo data are scarce, necessitating further research.